Prelude Therapeutics Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 15, 2023. This is an annual report, not a standalone fourth-quarter report. Prelude is a clinical-stage oncology company with no approved products and no product revenue.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $92.9 million | $86.8 million |
| General and administrative expense | $30.7 million | $27.0 million |
| Total operating expenses | $123.5 million | $113.7 million |
| Other income, net | $8.1 million | $2.0 million |
| Net loss | $115.4 million | $111.7 million |
| Net loss per share, basic and diluted | $2.44 | $2.43 |
| Cash used in operating activities | $83.7 million | $83.5 million |
- Year-end cash, cash equivalents and marketable securities totaled $201.7 million; restricted cash was an additional $4.0 million. Management expected available funds to cover operating expenses and capital expenditures through Q4 2024, subject to assumptions and execution.
- Total assets were $220.5 million and stockholders’ equity was $195.4 million at year-end. Total liabilities were $25.1 million, including lease liabilities and accrued obligations. The balance sheet does not show a borrowings balance; the filing separately references a Silicon Valley Bank line of credit and uncertainty about future access.
- Operating cash use was essentially unchanged year over year. Investing activities provided $81.7 million in 2022, primarily from maturities of marketable securities; financing provided $0.8 million, versus $164.9 million in 2021, when the company completed a stock offering.
- Net loss margin is not meaningful because the company reported no revenue. Accumulated deficit reached $334.6 million. Stock-based compensation was $25.1 million in 2022.
Material changes and business developments
- Operating expenses rose $9.8 million, led by increased discovery-program spending and internal personnel costs. Research and development spending on discovery programs increased to $25.2 million from $17.7 million.
- Other income increased to $8.1 million, primarily reflecting Delaware research and development tax-credit and grant income, as well as interest income.
- Prelude discontinued internal development of its two PRMT5 clinical candidates in November 2022 to focus resources on CDK9, MCL1, CDK4/6 and SMARCA2 programs. The filing reports prior clinical activity for PRT811, including responses in selected patients, but the program was nevertheless discontinued.
- PRT3645 received IND clearance in July 2022 and its first patient was dosed in December. PRT3879, a SMARCA2 degrader, received IND clearance in October 2022. The filing describes PRT3879 as the candidate; some risk-factor text instead refers to “PRT3789,” a discrepancy investors may wish to check.
Outlook, commentary and risks
- Management aimed to generate proof-of-concept clinical data over the following 12–24 months and stated a goal of producing a new IND every 12–18 months. These are targets, not assured outcomes.
- For PRT2527, management expected solid-tumor dose-escalation data in the first half of 2023 and hematology dose and initial data in the second half. For PRT1419, it expected solid-tumor data in the first half and hematology dose and data in the second half of 2023. These were forward-looking expectations in the 10-K.
- PRT2527 was in Phase 1 testing in solid tumors. PRT1419 was in Phase 1 testing; the company reported general tolerability and no observed cardiotoxicity to date, but early clinical findings do not establish efficacy or safety in larger studies. PRT3645 had begun Phase 1 testing. The filing also reports IND clearance for PRT3879, with clinical entry timing not specified here.
- In February 2023, Prelude entered an agreement for BeiGene to supply zanubrutinib for further study in combination with PRT2527.
- Key risks include clinical failure or safety findings, patient enrollment and trial delays, competition, reliance on third-party manufacturers and trial operators, limited supply redundancy, patent uncertainty, and the need for additional capital after the stated cash runway. The company has no commercial infrastructure or product revenue.
- Contractual operating lease payments were reported at $44.6 million in total. The company also entered a lease for approximately 81,000 square feet at Chestnut Run; the filing reports $5.1 million of prepaid rent at year-end and notes the long-term lease would be recognized upon commencement.
- The filing discusses potential effects of inflation, COVID-19 disruptions and market risks. It also notes Silicon Valley Bank exposure through an operating account and a line of credit; the extent of any impact is not quantified in the provided filing text.
- Ernst & Young issued an unqualified audit opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor did not express an opinion on internal control effectiveness.
Important facts for investors to verify
- Whether cash, cash equivalents and marketable securities remain sufficient relative to trial plans, facility commitments and the projected Q4 2024 runway.
- The current status, enrollment, safety findings and data maturity of PRT1419, PRT2527, PRT3645 and PRT3879, including whether the stated 2023 milestones were achieved.
- The “PRT3789” versus “PRT3879” naming discrepancy in the filing’s risk disclosures.
- The amount, terms and current availability of the referenced Silicon Valley Bank credit line, and any operating-account exposure.
- The timing and cash implications of the Chestnut Run lease, grant conditions and the reported $44.6 million of lease commitments.
- Whether additional financing will be needed sooner than management’s estimate and the likely effects of any financing on shareholder dilution.